Compass Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics targeting angiogenesis and the tumor microenvironment. The filing covers the quarter and six months ended June 30, 2023, and was filed August 3, 2023. The company has no product revenue and remains dependent on equity financing and other capital sources.
- Lead programs: CTX-009, CTX-471 and CTX-8371.
- Development status: CTX-009 and CTX-471 were in clinical development; CTX-8371 was targeted for an FDA IND submission in the third quarter of 2023 and clinical-trial initiation in the fourth quarter of 2023.
- Research strategy: In January 2023, internal research activities were redirected from early-stage discovery toward translational research and preclinical development support.
Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $10.2 million in 2023 vs. $5.9 million in 2022 | $16.9 million in 2023 vs. $10.3 million in 2022 |
| General and administrative expense | $3.1 million vs. $3.1 million | $6.2 million vs. $5.9 million |
| Total operating expenses | $13.3 million vs. $9.0 million | $23.0 million vs. $16.2 million |
| Net loss | $11.3 million vs. $8.5 million | $19.1 million vs. $15.7 million |
| Net loss per share | $0.09 vs. $0.08 | $0.15 vs. $0.16 |
| Other income | $2.1 million vs. $0.5 million | $3.9 million vs. $0.5 million |
| Net cash used in operating activities | Not separately provided | $22.3 million vs. $12.5 million |
Operating and profit margins are not meaningful because the company has no revenue. Interest income substantially increased due to the company’s investment portfolio and higher interest rates, partially offsetting operating losses.
- Liquidity: Cash and cash equivalents were $19.3 million at June 30, 2023, compared with $34.9 million at December 31, 2022. Marketable securities were $149.5 million, compared with $151.7 million.
- Total liquidity: Cash, cash equivalents and marketable securities totaled approximately $168.8 million, or approximately $169 million.
- Assets and equity: Total assets were $179.2 million and stockholders’ equity was $168.3 million at June 30, 2023.
- Debt and obligations: The filing does not report debt financing or borrowings. Lease liabilities totaled $2.3 million, including $1.1 million current and $1.2 million long term.
- Cash flow investing activity: Investing activities provided $3.6 million, primarily from net sales or maturities of marketable securities.
- Financing activity: Financing activities provided $3.1 million, including approximately $3.0 million of net ATM proceeds.
- Accumulated deficit: $291.9 million at June 30, 2023.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense increased 74% to $10.2 million, primarily due to higher CTX-009 manufacturing and clinical costs. CTX-009 spending increased by $5.9 million year over year.
- Six-month research and development expense increased 64% to $16.9 million. CTX-009 spending increased from $1.5 million to $10.8 million, while spending on CTX-471 and CTX-8371 declined.
- Six-month operating cash use increased to $22.3 million from $12.5 million.
- Interest income increased to $3.9 million for the six months from $0.5 million in the prior-year period.
- The company sold 951,873 shares under its ATM agreement through June 2023 for gross proceeds of $3.1 million and net proceeds of approximately $3.0 million.
- Marketable securities declined modestly in carrying value, while the portfolio was repositioned through purchases, sales and maturities. The company reported $0.2 million of net unrealized losses for the six months.
- Accrued expenses declined to $7.8 million from $11.7 million, although project expenses included approximately $6.5 million of accrued manufacturing costs for CTX-009, including $5.3 million of minimum contractual obligations.
Guidance, Outlook, Risks and Unusual Items
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into 2026 based on current plans. This estimate includes a Phase 2/3 and two Phase 2 CTX-009 trials, a Phase 1b CTX-471 combination trial and a Phase 1 CTX-8371 trial.
- Management expects additional funding will be required to complete clinical development, commercialize any approved products and pursue additional in-licenses or acquisitions.
- For CTX-009, the company expected an interim readout from the metastatic colorectal cancer Phase 2 trial in the second half of 2023. The CTX-009 biliary tract cancer Phase 2/3 trial had opened 20 sites, with top-line data expected in the second half of 2024.
- For CTX-471, enrollment in the dose-escalation portion of the pembrolizumab combination study was completed in July 2023, with interim data expected in the second half of 2023.
- The company expected to submit an IND for CTX-8371 in the third quarter of 2023 and initiate a clinical trial in the fourth quarter of 2023.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, manufacturing and supply-chain constraints, the need for additional capital, dilution from future equity financing, dependence on collaborators and key personnel, intellectual-property risks, competition and the absence of product revenue.
- The filing notes prior delays in sourcing selected clinical-trial manufacturing supplies related to COVID-19 and states that further delays could affect trial timing.
- Potential future obligations include ABL Bio development and regulatory milestones, commercial milestones and royalties for CTX-009, as well as up to $2.0 million of potential future milestone payments under the Adimab agreement.
- The company reported no material legal proceedings, no material related-party transactions and no income tax expense for the periods presented.
- Management concluded that disclosure controls and procedures were effective as of June 30, 2023, with no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Whether CTX-009, CTX-471 and CTX-8371 meet the stated clinical, regulatory and enrollment milestones.
- Whether the projected liquidity runway to 2026 remains valid as clinical and manufacturing spending increases.
- The pace of operating cash burn and the timing, size and terms of any future equity, debt or strategic financing.
- CTx-009 manufacturing obligations, including the reported $5.3 million of minimum contractual commitments and additional potential license payments.
- Interim and top-line clinical data, particularly the CTX-009 colorectal and biliary tract cancer programs and the CTX-471/pembrolizumab study.
- The company’s ability to advance programs without material trial delays, supply constraints, adverse safety findings or additional regulatory requirements.
- Potential shareholder dilution from the ATM program, equity compensation and future capital raises.